After explant, how do you separate a lift from volume with your own fat?
People shopping for preparation support after implant removal are usually trying to answer a planning question, not a product question. This livestream focused on three decisions that get collapsed online: removal, skin and nipple position, and volume. Products sit downstream of that plan. They do not replace it.
Start with three questions, not a kit
Dr. Whitfield treats explant, a lift, and fat transfer as related tools with different jobs. Explant removes the device and, in his practice, the capsule. A lift reshapes loose skin and may reposition a nipple that sits substantially below the fold. Fat transfer can add volume. It cannot lift. It cannot raise a low nipple. It cannot recreate an implant profile. Photographs cannot show tissue thickness or most capsule findings. History, examination, and sometimes imaging come first.
Explant can be done without a lift and without fat. If someone is not comfortable with extra scars, the lift is deferred. Volume removal can still let tissues settle lower. That possibility belongs in the consent conversation before the operating room.
Fat is volume, not a spare implant
Fat is not one to one with implant volume. He does not place it in the old pocket. It belongs in the fatty plane under the skin. Over-grafting creates contour problems. Donor sites bruise and swell. The lateral thigh is often the most sensitive. Oil cysts and fat-necrosis findings can appear on imaging. Tell the radiology team that fat transfer was performed. Combination surgery is gated behind preparation.
For donor-site laxity he offers BodyTite and Morpheus8 as optional adjuncts after individualized analysis and consent. They are not required to buy, book, or recover. They are not sold in a cart as a substitute for choosing the right operation, or choosing explant alone.
Why preparation products only make sense after the plan
He described a long view of preparation and recovery: where someone has lived and worked, implant surface and pocket, prior operations, pregnancies, weight change, medications, habits, and imaging. For lower body-weight patients considering fat transfer, he uses a DEXA scan with examination rather than BMI alone. Supportive in-office tools were listed as adjuncts some patients in his practice may use. They are not a substitute for surgical judgment, and they are not appropriate for every person after every operation.
If you and your clinician are already working on surgical readiness, the SHARP book is the practice's written map of that framework. It is reading and structure, not a treatment. Any testing decision belongs with your own provider. Tests are informational. They do not diagnose a disease and they do not prescribe a supplement.
SHARP book: https://www.drrobssolutions.com/products/sharp-by-dr-robert-whitfield
Inflammation test: https://www.drrobssolutions.com/products/inflammation-test
Mini SHARP course: https://www.drrobssolutions.com/products/mini-sharp-method-course-with-dr-whitfield
SHARP on the practice site: https://www.drrobertwhitfield.com/sharp
Store home: https://www.drrobssolutions.com
Molecular findings are not a shopping list
Molecular findings from submitted explant specimens were mentioned in the talk. Keep the published limit: 203 of 694 submitted capsule and tissue specimens (about 29 percent) had positive targeted 16S findings (PMID 39338504). That is a rate among submitted specimens, not among all people with implants. Detection of bacterial DNA fragments associated with biofilm does not establish that organisms were alive, that a clinical infection is present, or that any one person needs a specific treatment. That is not a population rate for everyone with implants, and it is not a reason to order a cart. It is one reason he tries to remove capsule tissue when he can.
What this livestream actually taught
The talk was built around a planning problem, not a product. After implant removal, people often collapse three different questions into one screenshot. He separated them. First, should the implant come out, and how is the capsule handled in that operation. Second, what is happening with the skin envelope and the nipple position relative to the fold. Third, if volume is desired after the device is gone, what can fat transfer realistically add. Those questions are related. They are not the same operation, the same scar, or the same recovery.
He was explicit that explant alone is always an option. A lift is considered when the nipple sits substantially below the fold, not because an implant receipt listed a certain size. Fat is used for volume. Fat cannot lift loose skin. Fat cannot raise a low nipple. Fat cannot recreate the projection profile of an implant. Density is different. Placement is different. He does not put fat into the old implant pocket. In his description, fat belongs in the fatty plane beneath the skin, above the breast tissue.
Results after explant vary. Implant size, how long the device has been in place, skin quality, tissue thickness, and starting nipple position all change what the breast looks like once the volume of the device is gone. That is why a photograph is a conversation starter and not a surgical plan. Tissue thickness, how the skin will recoil, and most of the scar tissue around a device are not visible in a still image.
When someone wants volume after removal, he described fat harvest from typical donor areas, with the lateral thigh often the most sensitive. Swelling, bruising, and discomfort at donor sites are expected risks. Over-grafting, in his view, creates many of the contour problems people worry about later. Oil cysts and areas that look like fat necrosis can show up on ultrasound or mammogram. The imaging team needs to know that fat transfer was performed. Fat transfer has been used in reconstructive settings for many years. Additional imaging may still be needed if a finding is unclear. That is not the same as a claim that screening never changes.
For donor-site contour, he offers deeper tightening with BodyTite and more superficial treatment with Morpheus8 as optional adjuncts after individualized analysis and consent. They are not a required bundle and they are not a facelift of the breast. A lift, when it is chosen, reshapes the envelope and repositions the nipple-areolar complex. Combining removal, a lift, and fat transfer in one anesthetic is one option after preparation. If another surgeon recommends staging, he said that can be a reasonable plan when the person understands it.
Pocket location changes the work of capsule removal. When the implant sits in front of the muscle, access is more direct. When it sits behind the muscle, the muscle is reflected and the capsule along the rib cage and the underside of the muscle has to be addressed, then the muscle is repaired. That is anatomy teaching, not a promise that every capsule comes out as one unbroken specimen in every body. Capsule management is individualized.
He described trying to remove capsule because debris from an implant shell can rest in that tissue, and because published molecular work on submitted specimens found bacterial DNA in a minority of those samples. Keep the published limit. 203 of 694 submitted capsule and tissue specimens (about 29 percent) had positive targeted 16S findings (PMID 39338504). That is a rate among submitted specimens, not among all people with implants. Detection of bacterial DNA fragments associated with biofilm does not establish that organisms were alive, that a clinical infection is present, or that any one person needs a specific treatment. A food-poisoning story from the livestream was a single unusual case, not a typical explant presentation, and it is not used here as a population claim.
Preparation in his practice is a long horizon. History, implant surface, pocket, prior operations, pregnancies, weight change, medications, habits, and existing imaging all belong in the chart before anyone is asleep. For lower body-weight patients considering fat transfer, he said he uses a DEXA scan together with examination rather than BMI alone. That is his planning tool. It is not a public screening test and it does not assign candidacy from a comment. In-office tools he named, including hyperbaric oxygen, the Human Regenerator, Flowpresso, red light, and NanoVi, were framed as adjuncts some patients in his Austin office may use. They are not a universal recovery protocol and they are not a substitute for the operation you actually need, or do not need.
FAQ
Does everyone need a lift after explant? No.
Does fat transfer replace implant volume? No. Density and location are different.
Does fat lift a low nipple? No.
Is combination surgery required? No. Staging can be appropriate.
Are store items required to have surgery? No. Surgery candidacy is clinical.
Do molecular findings in a published specimen series diagnose my capsules? No.
The SHARP framework
Preparation is not an extra. In this talk, Dr. Whitfield described how history, implant type, pocket location, prior operations, pregnancies, weight change, medications, habits, and imaging all belong in the plan before anyone is in an operating room. He also described recovery as individualized stacking of nutrition, supplementation when appropriate, sleep, walking, and in-office supportive therapies rather than one protocol for every procedure.
The SHARP approach, Strategic Holistic Accelerated Recovery Program, is the practice framework used to organize that work: evaluate the whole picture, prepare the person, operate with a safety-first plan, then support recovery. It is not a promise that swelling, sensation, donor-site contour, or scars will follow one timeline.
Learn more about SHARP: https://www.drrobertwhitfield.com/sharp
SHARP book: https://www.drrobssolutions.com/products/sharp-by-dr-robert-whitfield
Next step
If you want individualized information about explant, lift, and fat-transfer planning, schedule a Discovery Call.
Discovery Call: https://discovery.drrobertwhitfield.com/form
Disclaimer
This material is educational and is not medical advice, a diagnosis, or a treatment plan. It does not establish a physician-patient relationship. Individual findings, imaging, and in-person examination determine what is appropriate. Consult your own licensed clinician before making medical decisions.
203 of 694 submitted capsule and tissue specimens (about 29 percent) had positive targeted 16S findings (PMID 39338504). That is a rate among submitted specimens, not among all people with implants. Detection of bacterial DNA fragments associated with biofilm does not establish that organisms were alive, that a clinical infection is present, or that any one person needs a specific treatment.